Docs use 3-D printed models to prepare for surgery; Big Data healthcare consultancy raises $17.5M;

@FierceMedDev: UPDATED with interview of CEO: TAVR maker JenaValve receives $26.5M to fund U.S. studies. Report | Follow @FierceMedDev

@VarunSaxena2: Crowdsourcing challenge winner looking to commercialize NIH tech to diagnose brain cancer. Article | Follow @VarunSaxena2

@EmilyWFierce: Congress urges feds to probe FDA over morcellator safety concerns. More | Follow @EmilyWFierce

> Four children with malformed blood vessels in their brain benefited from 3-D printing of their anatomy prior to the high-risk corrective procedures. "These children had unique anatomy with deep vessels that were very tricky to operate on," said Boston Children's neurosurgeon Dr. Edward Smith. "The 3-D-printed models allowed us to rehearse the cases beforehand and reduce operative risk as much as we could. You can physically hold the 3-D models, view them from different angles, practice the operation with real instruments and get tactile feedback." More

> Zephyr Health raised $17.5 million in equity. The company uses Big Data to offer market insights to medical device and pharma companies. More

> Waste management company Rubicon Global is expanding its focus to include the disposal of waste produced by hospitals. More

Biotech News

@FierceBiotech: AstraZeneca offers $727M package to partner with Inovio on immuno-oncology. News | Follow @FierceBiotech

@JohnCFierce: Sanofi takes another stab at cancer with Evotec, Apeiron checkpoint partnership. Article | Follow @JohnCFierce

@DamianFierce: Like most people, I'm waiting for Thug_BioAnalyst to weigh in before I form an opinion on anything this morning. | Follow @DamianFierce

> Karyopharm tanks as sepsis scares plague its cancer contender. Article

> Sorrento's biotech buyouts bag CAR-T drugs. Item

> Gates backs a $120M breakout round for CRISPR/Cas9 pioneers at Editas. Story

Pharma News

@FiercePharma: Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. FiercePharmaMarketing story | Follow @FiercePharma

@EricPFierce: ICYMI last week: Aprecia is building $25M plant where it will do 3D printing of drugs. Article | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday: Orexigen picks up new trial tab to settle Contrave dispute with partner Takeda. More | Follow @CarlyHFierce

> GSK defends low-margin strategy with a gloomy outlook for high drug prices. More

> Lilly chalks up a win for Cymbalta in first U.S. trial over withdrawal symptom claims. Article

Animal Health News

> Aratana continues to trim losses in Q2 as it focuses on animal treatments. News

> Merck to partner with National Milk Producers group on training and animal care. Report

> USDA grants conditional license to Zoetis for canine anti-itch therapy. Story

> Feds indict four with smuggling bogus pet products into the U.S. Item

> Dechra to buy control of Croatian animal vaccine maker for $56.4M. Article

Biotech IT News

> Apple's ResearchKit goes global as heart study expands into Hong Kong and U.K. Item

> IBM makes $1B bid for Merge to bolster Watson's image analytics capabilities. Report

> Teva buys majority stake in Immuneering to access genome analysis tools. More

> Illumina strikes deal to buy LIMS provider GenoLogics. Article

> FDA makes its first approval of a 3D-printed drug. Story

Pharma Marketing News

> Allergan plots Namzaric DTC campaign to shore up its Namenda defenses. Item

> Amarin case could unleash a flood of off-label promos. Report

> Novartis goes '80s with Cyndi Lauper-led psoriasis campaign. More

> Xtandi marketer Astellas scrums with rugby partners for prostate cancer awareness. Story

> Big Pharma feeds controversy by routing big bucks to private CME. Article